However, mutations caused by NRAS, KRAS, BRAF, PI3KCA, and Akt activation in cancers may confer the cancer cells’ therapeutic resistance to cetuximab and render it a less effective anti-cancer agent [320, 326]. This evidence concerns the gene BRAF and cancer.